Sutent is an orally-available small-molecule multiple receptor tyrosine kinase inhibitor. Receptor tyrosine kinases are implicated in a number of cell-cell signaling pathways governing angiogenesis, cell division and growth, and cell survival. By disrupting these systems, Sutent inhibits the ability of tumor cells to divide and grow.
Sutent is specifically indicated for the treatment of a pair on oncology indications: gastrointestinal stromal tumors (GIST) that are refractory to or have relapsed following treatment with imatinib; and advanced renal cell carcinoma (RCC).
Sutent is supplied as a hard gelatin capsule for oral administration. The recommended initial dose regimen is 50 mg once daily for 4 weeks, followed by 2 weeks off treatment. Dose may be adjusted up or down in 12.5 mg increments, based on patient response and tolerability.